Drug Profile
Sargramostim - Bayer HealthCare Pharmaceuticals/Partner Therapeutics
Alternative Names: BI 61012; GZ 402664; Leukine; Leukine Liquid; NPC-26; Prokine; Recombinant human GM‑CSF; rhuGM-CSF; Sargramostim - Bayer HealthCare Pharmaceuticals; sargramostim-biosimilarLatest Information Update: 22 Dec 2023
Price :
$50
*
At a glance
- Originator Amgen
- Developer Bayer HealthCare Pharmaceuticals Inc.; Cincinnati Children's Hospital Medical Center; Dana-Farber Cancer Institute; National Cancer Institute (USA); National Institute on Aging; Niigata University; Nobelpharma; Partner Therapeutics; Sanofi; University of California at Irvine; University of California at San Francisco; University of Colorado at Denver; University of Nebraska Medical Center; University of Texas M. D. Anderson Cancer Center; Virginia Commonwealth University
- Class Adjuvants; Anti-infectives; Antidementias; Antineoplastics; Antiparkinsonians; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors; Radioprotectives
- Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Sepsis
Highest Development Phases
- Marketed Acute radiation syndrome; Bone marrow disorders; Neutropenia; Pneumococcal infections; Stem cell mobilisation
- Preregistration Pulmonary alveolar proteinosis
- Phase III COVID 2019 infections
- Phase II Acute hypoxia; Alzheimer's disease; Chronic lymphocytic leukaemia; Haematological malignancies; Malignant melanoma; Mycobacterial infections; Prostate cancer; Skin cancer
- Phase I Unspecified
- Preclinical Down syndrome; Sepsis
- No development reported Ovarian cancer; Parkinson's disease
- Discontinued Crohn's disease; Follicular lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 20 Dec 2023 Efficacy and adverse events data from a phase II SCOPE trial in COVID-2019 infections released by Partner Therapeutics
- 30 Nov 2023 Clinical trials in Pulmonary alveolar proteinosis (SC) prior to November 2023
- 30 Nov 2023 Efficacy and adverse events data from a clinical trial in Pulmonary alveolar proteinosis released by Partner Therapeutics